Abstract
Eleven men with sexual deviation syndrome were hospitalized for treatmet with medroxyprogesterone acetate (Depo-provera). Plasma total cholesterol, triglycerides, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, apo A-I and LDL apo B were measured before and during Depo- provera treatment. Ten normolipidemic and one mildly hypertriglyceridemic patient with 117 ± 17% ideal body weight were maintained on a regular hospital diet before and during the study. They received an average total dose of 1273 ± 467 mg Depo-provera by im injections over a mean period of 17 ± 6 days. In the whole group, Depo-provera significantly reduced the plasma total cholesterol by 12% (p < 0.0005), triglycerides by 24% (p < 0.005), LDL cholesterol by 13% (p < 0.01), LDL apo B by 15% (p < 0.05), and apo A-I by 7% (p < 0.05). Total HDL cholesterol, HDL2 cholesterol and HDL3 cholesterol did not change significantly. Excluding from the data analysis a normolipidemic patient who had a significant weight loss during the study and the hypertriglyceridemic patient, the fall in apo A-I during Depo-provera treatment was no longer statistically significant. We conclude that short-term, pharmacological doses of progesterone significantly reduce plasma concentrations of cholesterol, triglycerides, LDL cholesterol, and LDL apo B in men.
Similar content being viewed by others
References
Heiss G., Tamir I., Davis C., Tyroler H., Rifkind B., Schonfeld G., Jacobs D., Frantz Jr I. Lipoprotein-cholesterol distributions in selected normal American populations. The Lipid Research Clinics Program prevalence study. Circulation 61: 302, 1980.
Cheung M.C., Albers J.J. The measurement of apolipoprotein A-l and A-ll levels in men and women by immunoassay. J. Clin. Invest. 60: 43, 1977.
Schaefer E.J., Foster D.M., Zech L.A., Lindgren F.T., Brewer Jr. H.B., Levy R.I. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J. Clin. Endocrinol. Metab. 57: 262, 1983.
Glueck C.J., Levy R.I., Fredrickson D.S. Norethindrone acetate, post-heparin lipolytic activity, and plasma triglycerides in type I, III, IV and V hyperlipoproteinemia. Ann. Intern. Med. 75: 345, 1971.
Barth A., Klinger W. Influence of phenobarbital, chlorpromazine, progesterone and phenylbutazone on the biliary cholesterol excretion in rats. Acta Biol. Med. Ger. 39: 1217, 1980.
Amatayakul K. The effects of Depo-provera on carbohydrate, lipids and vitamin metabolism. J. Steroid Biochem. 11: 475, 1979.
Fajumi J.D. Alterations in blood lipids and side effects induced by Depo-provera in Nigerian women. Contraception 27: 161, 1983.
Amatayakul K., Sivassomboon B., Singkamani R. Effects of medroxyprogesterone acetate on serum lipids, protein, glucose tolerange and liver function in Thai women. Contraception 21: 283, 1980.
Engelberg H., Glass S.J. Influence of physiologic doses of sex steroid hormones on serum lipids and lipoproteins in humans. Metabolism 4: 298, 1955.
Larsson-Cohn U., Berlin R., Vikrot O. Effects of combined and low-dose gestagen oral contraceptives on plasma lipids including individual phospholipids. Acta Endocrinol. (Kbh.) 63: 717, 1970.
Spellacy W.N., Buhi W.C., Birk S.A., Cabal R. The effects of estrogens, progestogen, oral contraceptives, and intrauterine devices on fasting triiglyceride and insulin levels. Fertil. Steril. 24: 178, 1973.
Donde U.M., Virkar K. The effect of combination and low dose progestogen oral contraceptives on serum lipids. Fertil. Steril. 26: 62, 1975.
Spellacy W.N., Newton R.E., Buhi W.C., Birk S.A. Carbohydrate and lipid studies during six months treatment with megestrol acetate. Am. J. Obstet. Gynecol. 116: 1074, 1973.
Lipid Research Clinics Manual of Laboratory Operations. Vol. 1 Lipid and lipoprotein analysis. Washington, DC. Government Printing Office. (9 DHEW publication no (NIH) 75-628), 1974.
Warnick G.R., Benderson J.M., Albers J.J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high density lipoprotein cholesterol. Clin. Chem. 28: 1379, 1982.
Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 18: 499, 1972.
Maciejko J.J., Holmes D.R., Kottke B.A., Zinsmeister A.R., Dinh D.M., Mao S.J.T. Apolipoprotein A-l as a marker of angiographically assessed coronary artery disease. N. Engl. J. Med. 309: 385, 1983.
Berlin F.S., Meinecke OF. Treatment of sex offenders with antiandrogenic medication: conceptualization, review of treatment modalities, and preliminary findings. Am. J. Psychiatry 138: 601, 1981.
Rivarola M.A., Camacho A.M., Migeon C.J. Effect of treatment with medroxyprogesterone acetate (Provera) on testicular function. J. Clin. Endocrinol. Metab. 28: 679, 1968.
Gutai J., LaPorte R., Kuller L., Dai W., Falvo-Gerard L., Caggiula A. Plasma testosterone, high density lipoprotein cholesterol and other lipoprotein fractions. Am. J. Cardiol. 48: 897, 1981.
Goldberg R.B., Rabirr D., Alexander A.N., Doelle G.C., Getz G.S. Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-l and B. J. Clin. Endocrinol. Metab. 60: 203, 1985.
Wahl P., Waiden C., Knopp R., Hoover J., Wallace R., Heiss G., Rifkind B. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N. Engl. J. Med. 308: 862, 1983.
Hirvonen E., Malkonen M., Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N. Engl. J. Med. 304: 560, 1981.
Silfverstolpe G., Gustafson A., Samsioe G., Svanborg A. Lipid metabolic studies in oophorectomized women: Effects of three different progestogens. Acta Obstet. Gynecol. Scand. (Suppl.) 88: 89, 1979.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chen, J.J.S., Berlin, F.S. & Margolis, S. Effect of large-dose progesterone on plasma levels of lipids, lipoproteins and apolipoproteins in males. J Endocrinol Invest 9, 281–285 (1986). https://doi.org/10.1007/BF03346926
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346926